Annex A: Implications/Anticipated impact

Risk implication and mitigation, including information on the risks of inaction

- Risks associated with the Facility are set out in the paper.

Impact on countries

- The failure of the Facility to provide up to 2 billion doses of COVID-19 vaccines by the end to 2021 will impact equitable access to COVID-19 vaccines, in particular for low-income economies.

Impact on Alliance

- The full Alliance is invested in the success of the COVAX Facility and COVAX AMC, with Gavi also seeking secondments to ensure that it is fully leveraging the expertise from across Alliance partners and stakeholders.

Legal and governance implications

- Gavi, as the legal entity of the Facility, will enter into the commitments with Participants of the Facility and manufacturers and will ultimately bear any exposure whether financial, programmatic or reputational.

- In addition, Gavi must ensure that the administration of the Facility is in accordance with the decision of the July meeting of the Board to that Gavi would leverage current governance bodies as well as develop new decision-making bodies to provide inclusive, transparent leadership of the COVAX Facility and COVAX AMC, and prohibiting Gavi from entering into commitments with manufacturers relating to SFPs which are not fully secured by committed resources from the Participants, with appropriate financial backing for such commitment, as assessed by the MSDC.